Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Perlegen, Pfizer collaboration to analyze patient DNA samples
February 2006
by Chris Anderson  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

MOUNTAIN VIEW, Calif.—Perlegen Sciences Inc. announced a new four-year research pact with Pfizer whereby researchers from both companies will conduct whole-genome studies involving DNA samples from clinical trials.
 
"We have continued to expand our relationship with Pfizer over time," says Paul Cusenza, senior VP of Perlegen "This latest collaboration will extend until December 2009 and is a [significant amount of research] in whole-genome and replication studies to identify genes that are associated with major diseases, as well as those that predict patient response to certain medicines."
 
The whole-genome association studies will examine, for instance, hundreds of patients with a specific "trait of interest" of either having a particular disease or particular responsiveness to a drug. The research will scan across the entire genome to identify SNPs and genetic variance among the patients to identify the associations and then following up the findings with validation studies.
 
Code: E020621

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.